文献速递前列腺癌

FUTURE试验:基于磁共振的前列腺癌靶向穿刺技术多中心随机对照试验

The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
PubMed 文献 · Eur Urol · 2018-12-03

FUTURE试验纳入665例既往系统穿刺阴性且持续怀疑前列腺癌的男性,先行3-T mpMRI,对234例PI-RADS≥3者按1:1:1随机接受FUS-TB、COG-TB或MRI-TB。三种MRI靶向穿刺技术在前列腺癌总体检出率(49%、44%、55%,p=0.4)和临床显著前列腺癌检出率(34%、33%、33%,p>0.9)上均无显著差异。

要点

  • mpMRI后PI-RADS≥3者三种靶向穿刺技术检出率无显著差异
  • 总体前列腺癌检出率FUS-TB 49%、COG-TB 44%、MRI-TB 55%,p=0.4
  • 临床显著前列腺癌检出率三组均为33%-34%,p>0.9

核心结论

  • 三种基于MRI的靶向穿刺技术对总体前列腺癌和临床显著前列腺癌的检出率均无显著差异。

研究设计与样本

  • 多中心随机对照试验,纳入665例既往系统穿刺阴性且持续怀疑前列腺癌的男性,2014至2017年在两家非学术教学医院和一家学术医院开展。
  • 所有患者接受3-T mpMRI并以PI-RADS第2版评估,PI-RADS≥3病灶者按1:1:1随机分配至FUS-TB、COG-TB或MRI-TB。

主要发现

  • 234/665(35%)患者mpMRI显示PI-RADS≥3病灶并接受靶向穿刺。
  • 总体前列腺癌检出率:FUS-TB 49%、COG-TB 44%、MRI-TB 55%,p=0.4。
  • 临床显著前列腺癌(Gleason评分≥3+4)检出率:FUS-TB 34%、COG-TB 33%、MRI-TB 33%,p>0.9。
  • FUS-TB与MRI-TB总体检出率差-5%(p=0.5,95%CI -21%至11%),FUS-TB与COG-TB差6%(p=0.5,95%CI -10%至21%),COG-TB与MRI-TB差-11%(p=0.17,95%CI -26%至5%)。
  • 临床显著前列腺癌检出率差:FUS-TB与MRI-TB 2%(p=0.8,95%CI -13%至16%),FUS-TB与COG-TB 1%(p>0.9,95%CI -14%至16%),COG-TB与MRI-TB 1%(p>0.9,95%CI -14%至16%)。

关键数值与推荐

  • 主要结局为总体前列腺癌检出率,次要结局为临床显著前列腺癌检出率(Gleason评分≥3+4),采用Pearson卡方检验比较。

临床怎么用

  • 对于既往系统穿刺阴性且持续怀疑前列腺癌的患者,mpMRI发现PI-RADS≥3病灶后,三种MRI靶向穿刺技术均可选择,检出率无显著优劣。

局限性

  • 主要局限性为mpMRI上PI-RADS≥3病灶比例较低,导致主要结局统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines advise multiparametric magnetic resonance imaging (mpMRI) before repeat biopsy in patients with negative systematic biopsy (SB) and a suspicion of prostate cancer (PCa), enabling MRI targeted biopsy (TB). No consensus exists regarding which of the three available techniques of TB should be preferred. OBJECTIVE: To compare detection rates of overall PCa and clinically significant PCa (csPCa) for the three MRI-based TB techniques. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomised controlled trial, including 665 men with prior negative SB and a persistent suspicion of PCa, conducted between 2014 and 2017 in two nonacademic teaching hospitals and an academic hospital. INTERVENTION: All patients underwent 3-T mpMRI evaluated with Prostate Imaging Reporting and Data System (PIRADS) version 2. If imaging demonstrated PIRADS ≥3 lesions, patients were randomised 1:1:1 for one TB technique: MRI-transrectal ultrasound (TRUS) fusion TB (FUS-TB), cognitive registration TRUS TB (COG-TB), or in-bore MRI TB (MRI-TB). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary (overall PCa detection) and secondary (csPCa detection [Gleason score ≥3+4]) outcomes were compared using Pearson chi-square test. RESULTS AND LIMITATIONS: On mpMRI, 234/665 (35%) patients had PIRADS ≥3 lesions and underwent TB. There were no significant differences in the detection rates of overall PCa (FUS-TB 49%, COG-TB 44%, MRI-TB 55%, p=0.4). PCa detection rate differences were -5% between FUS-TB and MRI-TB (p=0.5, 95% confidence interval [CI] -21% to 11%), 6% between FUS-TB and COG-TB (p=0.5, 95% CI -10% to 21%), and -11% between COG-TB and MRI-TB (p=0.17, 95% CI -26% to 5%). There were no significant differences in the detection rates of csPCa (FUS-TB 34%, COG-TB 33%, MRI-TB 33%, p>0.9). Differences in csPCa detection rates were 2% between FUS-TB and MRI-TB (p=0.8, 95% CI -13% to 16%), 1% between FUS-TB and COG-TB (p>0.9, 95% CI -14% to 16%), and 1% between COG-TB and MRI-TB (p>0.9, 95% CI -14% to 16%). The main study limitation was a low rate of PIRADS ≥3 lesions on mpMRI, causing underpowering for primary outcome. CONCLUSIONS: We found no significant differences in the detection rates of (cs)PCa among the three MRI-based TB techniques. PATIENT SUMMARY: In this study, we compared the detection rates of (aggressive) prostate cancer among men with prior negative biopsies and a persistent suspicion of cancer using three different techniques of targeted biopsy based on magnetic resonance imaging. We found no significant differences in the detection rates of (aggressive) prostate cancer among the three techniques.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wegelin O, Exterkate L, van der Leest M, et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2018. PMID: 30522912. doi:10.1016/j.eururo.2018.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。